Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETX2514-sulbactam versus placebo for complicated urinary tract infection
2017-002608-29Phase 2Completed
- Sponsor
- Entasis Therapeutics
- Start
- Oct 2017
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sulbactam and durlobactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Entasis Therapeutics. Primary endpoint: Overall success at test of cure in m-MITT population. Started Oct 2017; status: completed.
02
Drugs
sulbactamdurlobactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2017-002608-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002608-29.